Tablas – Toxina botulínica como tratamiento del déficit motriz en pacientes con parálisis cerebral infantil
Bibliografía
1. Jenicek M., Cleroux R. Epidemiología: La lógica de la medicina moderna. Barcelona: Masson 1996.
2. Conadis, datos estadísticos 2010-2012
3. Dask TK, Park DM. Botulinum toxin in treatment spasticity. Br J Clin Pharmacol 1989;43: 401-3.
4. Póo P, López-Casas JA, Galván-Manso M, Aquino-Fariña L, Terricabras-Carol L, Campistol J. Toxina Botulínica tipo A. Indicaciones y resultados. Rev Neurol 2003; 37: 74-80
5. Souayah N, Karim H, Kamin SS, McArdle J, Marcus S. Severe botulism after focal injection of botulinum toxin. Neurology 2006; 67: 1855-6.
6. Goldstein EM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 2006; 21: 189-2.
7. Linder-Lucht M, Kirschner J, Herrmann J. Why do children with cerebral palsy discontinue therapy with botulinum toxin A. Dev Med Child Neurol 2006; 48: 319-20.
8. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006; 13 (Suppl 4): 35-40
9. TurnerStokes L, Baguley IJ, De Graaff S, Katrak P, Davies L, McCrory P, et al. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary análisis from a doubleblind placebocontrolled randomized clinical trial. J Rehabil Med. 2010;42:819.
10. Frascarelli F, Masia L, Di Rosa G, Petrarca M, Cappa P, Castelli E. Robotmediated and clinical scales evaluation after upper limb botulinum toxin type A injection in children with hemiplegia. J Rehabil Med. 2009;41:98894.
11. Willoughby KL, Dodd KJ, Shields N. A systematic review of the effectiveness of treadmill training for children with cerebral palsy. Disabil Rehabil. 2009; 31:19719.
12. Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, et al; Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Practice parameter: pharmacologic treatment of spasticity in children and adolescents withcerebral palsy (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74:33643.
13. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, et al. The updated European Consensus 2009 on the use of botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010;14:4566.
14. SimpsonDM,GraciesJM, GrahamHK, MiyasakiJM, NaumannM, RussmanB,etal.,Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assess- ment: Botulinum neurotoxina for the treatment of spasticity (an evidence-based review):report of the Therapeutics andTech-nology Assessment Subcommittee of the American Academy of Neurology. Neurology.2008;70:1691—8.
15. Albavera-HernándezC, RodríguezJM, IdrovoAJ. Safetyofbotu- linum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. ClinRehabil.2009;23:394—407.
16. LimEC, SeetRC. Botulinum toxin: description of injection techniques and examination of controversias surroundding toxin diffusion. Acta Neurol Scand.2008;117:73—84.
17. Elovic EP, Esquenazi A, Alter KE, Lin JL, Alfaro A, Kae-lin DL. Chemodenervation an enerve blocks in the diagnosis and Management of spasticity and muscle overactivity. PMR. 2009;1:842—51.
18. Depedibi R, UnlüE, Cevikol A, Akkaya T, Cakci A, Cerekc¸i R, et al. Ultrasound-guided botulinum toxin type A injection to